Back
Speaker illustration

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

Heart Failure Cardiologist and Clinical Trialist at Duke University Medical Center and the Duke Clinical Research Institute. Chief of the HF Section at Duke. Editor in Chief of the Journal of Cardiac Failure - the Official Journal of the HFSA

Presentations Articles

Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Chronic heart failure - treatment 7

Access
Like
Thumbnail

Ferric carboxymaltose in heart failure with iron deficiency - the HEART-FID and AFFIRM-AHF trials

Event: Heart Failure 2024

Topic: Anaemia/Iron Deficiency

Session: Trials of IV iron: what we got right and what we didn’t. How can the new ESC guidelines help improving clinical practice?

Access
Like
Thumbnail

HEART-FID: a pragmatic trial in the US

Event: Heart Failure 2024

Topic: Comorbidities

Session: Comorbidities: how to treat, how to define iron deficiency

Access
Like
Thumbnail

Ask the Trialist - HEART-FID

Event: ESC Congress 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Ask the Trialists from Hot Line 2

Access
Like
Thumbnail

HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency

Event: ESC Congress 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: HOT LINE 2

Access
Like
Thumbnail

Interactive panel discussion

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session: Two decades of research on iron deficiency in heart failure: looking back and moving forward

Access
Like
Thumbnail

Moving forward - knowledge gaps and ongoing trials

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session: Two decades of research on iron deficiency in heart failure: looking back and moving forward

Access
Like
Thumbnail

PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Late breaking clinical trials: medical therapy

Access
Like
Thumbnail

Fundamentals in iron deficiency and IV iron

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session: IV iron: the story so far

Access
Like
Thumbnail

Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial

Event: Heart Failure 2021

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 2

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources